MACITENTAN (OPSUMIT®)

EXPANDING CLINICAL UTILITY AND CHARACTERIZE MACITENTAN IN NEW PAH PATIENT POPULATIONS


STAY COMMITTED TO POST-LAUNCH CHARACTERIZATION AND SAFETY ACTIVITIES


EXPANDING THE CLINICAL UTILITY OF MACITENTAN TO NEW CV INDICATIONS BEYOND PAH


• Gewillig M, Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. 2014 Jan;10(1):105-16


ACT-132577: ACTELION’S NEW ENDOTHELIN RECEPTOR ANTAGONIST

FURTHER UTILIZE THE ENDOTHELIN PATHWAY, BUILDING ON OUR ERA EXPERTISE


EXPANDING THE CLINICAL UTILITY OF SELEXIPAG

